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Abstract
MLN64 is an integral membrane protein localized to the late endosome and plasma membrane that is thought to function
as a mediator of cholesterol transport from endosomal membranes to the plasma membrane and/or mitochondria. The
protein consists of two distinct domains: an N-terminal membrane-spanning domain that shares homology with the
MENTHO protein and a C-terminal steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain that
binds cholesterol. To further characterize the MLN64 protein, full-length and truncated proteins were overexpressed in cells
and the effects on MLN64 trafficking and endosomal morphology were observed. To gain insight into MLN64 function,
affinity chromatography and mass spectrometric techniques were used to identify potential MLN64 interacting partners. Of
the 15 candidate proteins identified, 14-3-3 was chosen for further characterization. We show that MLN64 interacts with 14-
3-3 in vitro as well as in vivo and that the strength of the interaction is dependent on the 14-3-3 isoform. Furthermore,
blocking the interaction through the use of a 14-3-3 antagonist or MLN64 mutagenesis delays the trafficking of MLN64 to
the late endosome and also results in the dispersal of endocytic vesicles to the cell periphery. Taken together, these studies
have determined that MLN64 is a novel 14-3-3 binding protein and indicate that 14-3-3 plays a role in the endosomal
trafficking of MLN64. Furthermore, these studies suggest that 14-3-3 may be the link by which MLN64 exerts its effects on
the actin-mediated endosome dynamics.
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Introduction
MLN64 is an integral membrane protein localized primarily in
the late endosome [1,2]. Its N-terminus is homologous to another
late endosomal protein of unknown function called MENTHO,
with which it may interact [3,4]. Cross-linking studies indicate that
the MLN64 N-terminal domain may also bind cholesterol [4],
whereas overexpression of MLN64 leads to cholesterol accumu-
lation in the endosomal/lysosomal (E/L) compartment of COS1
cells, similar to depletion of NPC1 [5].
A role for MLN64 in cholesterol trafficking was first proposed
based upon its sequence homology to the functional region of
the steroidogenic acute regulatory (StAR) protein [2,6]. X-ray
crystallographic analysis of the START domain revealed the
existence of a hydrophobic cavity that could potentially
accommodate a single cholesterol molecule [7], supporting the
idea that MLN64 could function as a cholesterol transporter.
However, although the START domain of MLN64 can
promote cholesterol transport in vitro [8], targeted mutation of
this domain does not affect cholesterol metabolism in mice [9].
Although it is possible that this result can be explained by
species differences or the lack of an MLN64 null mouse model,
more questions are raised when considering that in the mouse
MLN64 was found to be largely absent from steroidogenic cells
[10].
To further investigate the function of MLN64 and its lipid
binding domains, different portions of the protein were overex-
pressed in mammalian cells and their effect on endosomal and
plasma membrane cholesterol levels as well as cholesterol
transport from the E/L system was examined. To further
characterize the function of MLN64, we identified candidate
interacting partners through a combination of affinity purification
and mass spectrometry and verified that MLN64 is a novel 14-3-3
interacting protein. Finally, we examined the effect of 14-3-3
binding on MLN64-mediated cholesterol trafficking as well as the
transport of MLN64 to the late endosome.
Results
Effects of MLN64 Overexpression
The MLN64 protein is composed of two distinct domains, the
N-terminal transmembrane domain, which has been shown to
bind cholesterol in the membrane [4] and the C-terminal cytosolic
START domain, which has been shown to mobilize cholesterol in
vitro [8] (Figure 1A). To evaluate the effect of MLN64
overexpression on cholesterol trafficking, constructs were gener-
ated encoding full-length MLN64, its START domain (START),
and the transmembrane domains (TM) (Figure 1B).
COS7 cells were cotransfected with the Flag-tagged MLN64
constructs and a CD63-YFP fusion construct to label the late
endosomes. Similar to previous results [1], MLN64, TM or
START overexpressing cells displayed cholesterol-filipin staining
at higher levels than untransfected cells. However, only the full-
length MLN64 and TM constructs colocalized in late
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an expression pattern characteristic of the endoplasmic reticu-
lum (ER) (Figure 1C), suggesting that endosomal targeting of
the protein requires the transmembrane domains of MLN64.
No further studies were carried out using the START domain
due to it’s inability to target to vesicles.
Figure 1. Expression studies of full length and truncated MLN64 protein. A) MLN64 is a late endosomal protein that consists of four
transmembrane segments and a cytosolic START domain. B) Schematic of full length and truncated MLN64 proteins containing only the
transmembrane domains (TM) or the cytosolic START domain (START). C) Expression of MLN64, TM or START (red signal) causes accumulation of free
cholesterol (blue signal) in the E/L system but only MLN64 and TM colocalize in late endosomes with CD63-YFP (green signal), whereas START
displays an expression pattern characteristic of the ER. D) Cells expressing MLN64 and TM, but not START, display enlarged endosomal vesicles at 24
hours post-transfection, and this phenotype becomes more pronounced after 72 hours.
doi:10.1371/journal.pone.0034424.g001
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further, the morphology of late endocytic organelles was examined
in cells expressing full-length MLN64 or the truncated constructs
for an extended period. At 24 hours, the MLN64 and TM
constructs localized to slightly enlarged endosomal vesicles
(Figure 1D), while the START domain displayed staining
characteristic of the ER as discussed above. However, at 72 hours
after transfection, the effect of full length MLN64 and TM
overexpression was grossly exacerbated and endocytic vesicles
appeared even further enlarged. The largest vesicles were found in
the TM-expressing cells (Figure 1D), suggesting a function for the
transmembrane portion of the protein in membrane dynamics.
To determine if MLN64 overexpression could affect LDL-
cholesterol transport to the ER for esterification, esterification
assays were performed in cells transfected with each of the three
MLN64 constructs. MLN64 overexpression did not cause a
significant change in esterification rates compared with untrans-
fected cells (data not shown), suggesting that MLN64 is not directly
involved in the delivery of LDL-cholesterol to ACAT in the ER.
Identification of Candidate MLN64-interacting Proteins
To probe further the function of MLN64 and its role in lipid
transport, the START domain of MLN64 was used for affinity
chromatography of human MCF7 cell extracts to isolate cytosolic
MLN64-interacting proteins. The START affinity column was
eluted with increasing salt concentrations and the resulting
fractions were separated by gel electrophoresis (Figure 2A). A
total of 15 proteins remained associated with START at high salt
concentrations and were excised from the gel and identified by
tandem mass spectrometry. Several of the identified proteins were
unknown while a number of proteins are known to reside in
cellular compartments that are distinct from the cytoplasmic
location of the MLN64 START domain (Table 1).
Thus, to further confirm and limit the number of potential
binding partners, a blot overlay experiment using recombinant
START protein was performed (Figure 2B). Six proteins bound
recombinant START on this overlay, including protein disulfide-
isomerase (PDI), sodium/hydrogen exchanger 3 (EBP50), hepato-
ma-derived growth factor (HDGF), heat shock protein 27 (Hsp27),
14-3-3, and MIR-interacting saposin-like protein (MSAP). Of
these six candidates, 14-3-3 was selected first for further analysis.
MLN64 is a Novel 14-3-3 Binding Protein
Since affinity purification and blot overlay showed that 14-3-3
can interact with the recombinant START domain of MLN64, its
interaction with full-length MLN64 was further investigated.
Bacterially expressed glutathione-S-transferase (GST)-tagged 14-3-
3 isoforms were used to pull down endogenous MLN64 from an
Huh7 cell lysate. Western blot analysis of MLN64 bound to 14-3-
3-GST beads showed that MLN64 can interact with most 14-3-3
isoforms, including the c, f, g, and t isoforms, with the strongest
binding shown by the g and t isoforms (Figure 3A). As an internal
control, a mutant 14-3-3 e isoform (e*) that cannot bind target
proteins [11] did not show any interaction with MLN64.
To determine whether MLN64 interacts preferentially with a
specific 14-3-3 isoform, equal amounts of MLN64-Flag-expressing
Huh7 cell lysates were incubated with each GST-14-3-3 isoform
and immunoprecipitated with anti-GST antibody. Western blot
analysis revealed that MLN64 bound most strongly to the 14-3-3
g isoform, less tightly to b and c isoforms, and weakly if at all to
the e* mutant, s and f isoforms (Figure 3B). These results varied
slightly from the results using endogenous MLN64 (Figure 3A),
however the g and t isoforms consistently bound very strongly to
MLN64, while the e* mutant and GST controls did not, indicating
a direct, strong interaction of MLN64 to 14-3-3.
Endogenous MLN64 Specifically Interacts with 14-3-3 In
vivo
To address the in vivo relevance of the MLN64-14-3-3
interaction, co-immunoprecipitations of endogenous proteins were
performed using CHO and MCF7 cell lysates. Endogenous
MLN64 protein was precipitated using a 14-3-3 antibody that
recognizes all seven 14-3-3 isoforms (14-3-3, H-8). An antibody
against Rab5, a GTPase associated with early but not late
endosomes, was used as a control. Samples were analyzed by SDS-
PAGE and then probed with an anti-MLN64 antibody. As shown
in Figure 4, a substantial amount of MLN64 can be precipitated
from both lysates with a 14-3-3 antibody but not with the Rab5
antibody. The reverse experiment using the MLN64 antibody to
precipitate 14-3-3 failed to detect an interaction between the two
proteins (data not shown). This result is most likely due to the fact
that the MLN64 antibody, which was raised against the START
domain, recognizes the epitope necessary for the specific
interaction with 14-3-3 and thus the interaction is blocked (see
below). To further confirm these results human cell extracts were
immunoprecipitated with antibodies against 14-3-3, MLN64 or
vimentin as a control followed by immunoblotting with an
anti=14-3-3 antibody. As shown in Figure 4B immunoprecipita-
tion of endogenous MLN64 coprecipitates 14-3-3 proteins whereas
immunoprecipitation with an anti-vimentin antibody, as a control,
does not (Figure 4B).
Generation of an MLN64 Mutant Deficient in 14-3-3
Binding
For many target proteins, 14-3-3 binding occurs on specific
phosphorylated serine and threonine residues [12]. Two optimal
14-3-3-binding phosphopeptide motifs, MODE I (RSXpSXP) and
MODE II (RXY/TXpSXP), have been isolated in oriented
peptide library screens [13]. The MLN64 protein does not contain
the canonical sequences reported in many 14-3-3 binding
partners, therefore to identify non-canonical binding sites we
utilized the MiniMotif Miner application, a database prediction
tool that focuses on identifying small subsets of short motifs [14].
This tool was validated by analyzing thousands of confirmed
examples of protein motifs as well as by confirming predictions of
previously unidentified 14-3-3 motifs in EFF-1, a Caenorhabditis
elegans protein found to be necessary and sufficient for most
somatic cell fusions in development [15].
Using MiniMotif Miner, an atypical binding site was identified
in the MLN64 protein sequence at position 392 of the START
domain (KSASNP) (Figure 5A). This C-terminal site displays a
high degree of similarity with the canonical MODE I motif of the
consensus binding motifs. To investigate whether this predicted
site was indeed required for 14-3-3 binding, a putative binding
mutant was generated by alanine substitution. Based on the known
crystal structure of the MLN64 START domain, the identified site
appears as a small loop on the surface of the protein (Figure 5B).
To preserve structural kinks imposed by the proline residue in the
START domain, the proline in the last position of the C-terminal
motif (KSASNP) was preserved.
TodeterminewhetherthemutantMLN64proteincouldbind14-
3-3invitro,GSTpulldownexperimentswerecarriedoutusinglysates
from Huh7 cells transfected with either MLN64-Flag (Wt) or
MLN64*-Flag (Mutant) and the 14-3-3 g isoform that showed the
highest degree of binding to Wt MLN64 (Figure 3A). Mutant
MLN64 exhibited only weak binding to 14-3-3 g compared to the
14-3-3 Binding to MLN64
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contributes to the interaction between MLN64 and 14-3-3.
Furthermore, the low levels of binding to the mutant protein may
beduetoretentionoftheterminalprolineinthe14-3-3bindingsite.
As expected, neither the Wt nor mutant MLN64 proteins displayed
any binding to the 14-3-3 e* negative control.
As further support for this conclusion the equal amounts of
mutant MLN64*-Flag-expressing Huh7 cell lysates were incubated
Figure 2. Identification of MLN64-interacting proteins. A) Proteins bound to a START-affinity column were eluted with 0.1–1.5 M NaCl and
resolved by gel electrophoresis. Proteins that remained associated at 0.4 M NaCl were isolated from the gel and identified by mass spectrometry. B)
The 0.4 M NaCl elution fraction was also subjected to a blot overlay experiment using recombinant START protein to confirm potential binding
partners.
doi:10.1371/journal.pone.0034424.g002
Table 1. MLN64-interacting proteins identified by mass spectrometry.
Band Protein Identifier
1 Heat shock protein HSP 90-alpha (HSP 86) GI: 14124932
2 Protein disulfide isomerase (PDI) GI: 4758304
3 Stress-induced phosphoprotein 1 (Hsp70/Hsp90-organizing protein) GI: 5803181
4 CAA28775.1 Hypothetical protein GI: 35655
5 Calreticulin GI: 4757900
6 Solute carrier family 9, sodium/hydrogen exchanger (EBP50) GI: 4759140
7 AAH17450 Unknown GI: 16924319
8 Hepatoma-derived growth factor (HDGF) GI: 4758516
9 Heat shock protein 27 (HSP27) GI: 662841
10 14-3-3 Protein tau GI: 1526541
11 Tumor protein D52 GI: 4827038
12 MIR-interacting saposin-like protein (MSAP) GI: 7657176
13 Chromatin modifying protein 4a (CHMP4) GI: 315259102
14 Eukaryotic translation initiation factor 5A-1 (eIF5AI) GI: 4503545
15 Mitochondrial import inner membrane translocase subunit (Tim8A) GI: 7305577
doi:10.1371/journal.pone.0034424.t001
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GST antibody as was shown for Wt MLN64 in Figure 3A above.
As shown in Figure 5D there was very little, if any, interaction of
mutant MLN64*-Flag with the various 14-3-3 isoforms.
Mutation of the 14-3-3 Binding Site Delays Trafficking of
MLN64 to the Late Endosome
The normal trafficking itinerary of MLN64 in the cell involves
traveling first to the plasma membrane before being targeted to
the late endocytic compartment [8]. Subcellular localization
studies have shown that MLN64 co-localizes partially with
markers associated with early, recycling and sorting endosomes
but is predominantly associated with late endosomal vesicles [1].
These observations suggest that MLN64 may move dynamically
through the endocytic pathway and that disruption of its
trafficking may affect its function. To determine if Wt and mutant
MLN64 proteins trafficked to the appropriate cellular compart-
ment (late endosome), Flag-tagged MLN64 constructs were co-
expressed with a CD63-YFP fusion protein, which serves as a
marker for late endosomal vesicles as well as the plasma
membrane. Immunofluorescence staining at 24 hours post-
transfection revealed largely late-endosomal staining for Wt
MLN64 as indicated by co-localization with CD63 (Figure 6A,
Wt).
However, some differences in localization patterns became
apparent in the 14-3-3 binding mutant of MLN64, which
appeared to accumulate at the plasma membrane much more
than the Wt MLN64 protein (Figure 6A, Mut). These results are
consistent with published data indicating that MLN64 traffics to
the plasma membrane prior to reaching its final destination on the
late endosomes [8] and furthermore indicates that this trafficking is
affected by mutation of the putative C-terminal 14-3-3 binding site
of MLN64.
Given the potential importance of MLN64 in cholesterol
trafficking we next determined whether overexpression of Wt
and mutant MLN64 proteins could cause cholesterol accumula-
tion in the E/L system. Consistent with our previous results
(Figure 1C), expression of the Wt and mutant MLN64 proteins
caused cholesterol accumulation in the E/L system and further-
more, the mutant MLN64 protein caused a higher degree of
accumulation than the Wt protein (Figure 6B, 6C). Cells were also
stained with the cholera toxin B subunit to label the monosialote-
trahexosyl ganglioside (GM1). Expression of the mutant MLN64
protein did not affect the levels of GM1 in late endocytic vesicles
relative to the Wt protein (Figure 6B); however, the amount of
GM1 in transfected cells was higher than in the untransfected
control (not shown).
To further characterize the effect of the 14-3-3 mutation on
MLN64 trafficking, cells expressing Wt or mutant MLN64 protein
were subjected to a 20uC temperature block in order to cause an
accumulation of the protein at the Golgi [16]. Cells were then
released from the temperature block and MLN64 trafficking was
examined by analysis of GFP fluorescence at 0, 15 and 30 minutes
after release from the block (Figure 7A).
Figure 3. MLN64 interacts with 14-3-3 in vitro. A) Western blot analysis of endogenous MLN64 from cell lysates bound to purified GST-tagged
14-3-3 isoforms indicates interactions between MLN64 and 14-3-3 c, e, g, f, t and s isoforms. e* denotes a 14-3-3 mutant that cannot bind target
proteins. B) Western blot analysis of purified Flag-tagged MLN64 bound to purified 14-3-3-GST isoforms indicates the strongest interactions with the
14-3-3 g and t isoforms.
doi:10.1371/journal.pone.0034424.g003
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Golgi after the temperature block (Figure 7A, 0 min). However, at
15 minutes after release from the block, only Wt MLN64 protein
could be detected in vesicular compartments and the plasma
membrane, in contrast to the mutant, which remained primarily in
the Golgi complex (Figure 7A, 15 min). Only a small population of
mutant protein was seen in endocytic vesicles after 30 minutes,
compared with almost all of the Wt protein (Figure 7A, 30 min).
That some of the mutant protein does eventually reach endocytic
organelles suggests that the effect of the mutation is to delay
delivery of the protein to the late endosome after release from
temperature block.
The effect of 14-3-3 binding on MLN64 trafficking was also
probed by expression of the 14-3-3 antagonist R18 peptide, which
when bound to 14-3-3 blocks ligand interactions [17]. This
construct, named DIFOPEIN (dimeric fourteen-three-three pep-
tide inhibitor), is a YFP fusion of two tandem R18 coding
sequences separated by a short peptide linker [18]. Twenty-four
hours following transfection with DIFOPEIN-YFP, cells were
probed with an anti-MLN64 antibody to detect the endogenous
protein. MLN64 localized to vesicular structures in both
DIFOPEIN-YFP-expressing and YFP-expressing cells (Figure 7B,
red). However, while MLN64-positive vesicles retained a charac-
teristic perinuclear morphology in cells expressing YFP alone, they
seemed to disperse toward the periphery of the cell in cells
expressing DIFOPEIN-YFP (Figure 7B). Similarly, when Flag-
tagged MLN64 was co-expressed with DIFOPEIN-YFP, MLN64-
positive organelles were localized to the cell periphery (Figure 7C).
These results further indicate that 14-3-3 binding is involved in
proper trafficking of MLN64 to endocytic vesicles.
The effect of DIFOPEIN on MLN64 trafficking was further
examined by subjecting cells transfected with Wt MLN64 and
DIFOPEIN-YFP to a temperature block at 20uC as described
above. Incubation at 20uC caused accumulation of the protein in
the Golgi in cells co-expressing DIFOPEIN-YFP and MLN64 as
well as in cells co-expressing YFP alone and MLN64 (Figure 7D,
t=0). In cells co-expressing YFP and MLN64, a vesicular pattern
of MLN64 expression was detected at 30 minutes after release
from the block (Figure 7D). This pattern is similar to that observed
with Wt MLN64 alone (Figure 7C). In cells co-expressing
DIFOPEIN-YFP with MLN64, MLN64 was still predominantly
localized to the plasma membrane, with only a small population
found in vesicular structures (Figure 7D), lending further support
that loss of 14-3-3 binding causes the trafficking delay observed in
the mutant MLN64.
Discussion
The mechanisms by which cholesterol is exported from late
endosomes are not yet clear, but MN64 is implicated in this
process due to several observations. The C-terminal START
domain of MLN64 has the ability to mobilize cholesterol transport
to steroidogenic mitochondria in vitro [8] while the N-terminal
transmembrane domain has also been shown to bind cholesterol
[4]. Although the precise function of MLN64 is still unknown,
overexpression of MLN64 has recently been shown to induce
expression of the cholesterol efflux regulatory protein ABCA1 [19]
and to mediate efflux of cholesterol from late endosomes to
mitochondria [20].
Overexpression of MLN64 leads to the appearance of enlarged
vesicles, an effect that is also seen when the transmembrane N-
terminal portion of the protein but not the C-terminal START
domain is overexpressed (Figure 1D). This phenomenon is
consistentwithpreviousstudies[4]andsuggeststhattheN-terminal
domain influences endosomal membrane dynamics. Our results
(Figure 1C), in agreement with others’ [1], also indicate that the N-
terminal domain of MLN64 is responsible for its endosomal
localization, since overexpression of a truncated protein consisting
ofonlytheSTARTdomainresultsinERlocalization. Interestingly,
our results also indicate that mutation of the 14-3-3 binding site
in the START domain of MLN64 causes accumulation of the
protein at the Golgi and delayed arrival at endosomes
(Figure 7A), suggesting that the interaction between MLN64
and 14-3-3 can also affect the localization of MLN64 (see
below).
Affinity chromatography using the START domain of MLN64
pulled out a number of proteins that potentially interact with
MLN64. Because there are 15 mammalian proteins containing
START domains, it is possible that the proteins we identified can
interact with one or more of the other START domain-containing
proteins, which could explain why proteins such as the
mitochondrial import inner membrane translocase subunit
(Tim8A) were identified using a cytoplasmic START domain.
Here we show that MLN64 can interact with the cytosolic
protein 14-3-3. The 14-3-3 proteins are a group of highly
conserved, multifunctional proteins that are involved in such
Figure 4. MLN64 interacts with 14-3-3 in vivo. A) Western blot
analysis of endogenous MLN64 from cell lysates immunoprecipitated
with an antibody that recognizes all seven 14-3-3 isoforms indicates
that MLN64 and 14-3-3 interact in vivo. The small amount of protein
precipitated with the Rab5 antibody most likely represents a population
in transit to the late endosome. B) Human cell extracts were
immunoprecipitated using anti-14-3-3, anti-MLN64 or anti-vimentin
antibodies. Precipitates were analyzed by Western blot probed for the
presence of 14-3-3 proteins.
doi:10.1371/journal.pone.0034424.g004
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protein trafficking [21]. The exact functions of the seven 14-3-3
isoforms has not yet been elucidated, so the significance of the
apparent preference of MLN64 for the g and t isoforms, and to a
lesser extent the b, c, and e isoforms, is not clear.
While 14-3-3 proteins often interact with phosphoserine or
phosphothreonine residues in their ligands, they can also interact
in a phosphorylation-independent manner with some ligands,
including human telomerase [22], the amyloid beta-protein
precursor intracellular domain fragment [23], and ExoS, a bi-
functional type III cytotoxin produced by Pseudomonas aeruginosa
[24]. MLN64 does not contain the conventional binding motifs
that are present in most 14-3-3 binding proteins [25] but we have
identified a non-canonical binding site in the START domain that
mediates the interaction between MLN64 and 14-3-3, which our
studies indicate is not dependent on phosphorylation (data not
shown). When this site is mutated, the resulting protein interacts
much less strongly to 14-3-3 in comparison to the Wt protein
(Figure 5C). Furthermore, a higher amount of the mutant MLN64
protein accumulates at the plasma membrane in comparison to
the Wt protein, which is predominantly located in endocytic
vesicles (Figure 6A); temperature block studies indicate that this
phenomenon occurs because trafficking of the mutant protein
from the plasma membrane to endocytic vesicles is delayed
(Figure 7). Taken together, these results suggest that the non-
canonical binding site in the START domain is important for the
MLN64-14-3-3 interaction and that this interaction affects the
trafficking of the MLN64 protein.
Much of the evidence that implicates 14-3-3 proteins in
trafficking comes from studies investigating the regulation of the
forward transport of signaling proteins and ion channels from the
ER to the plasma membrane [26,27,28]. There have also been
observations that 14-3-3 proteins affect the nuclear localization of
proteins [22,29]. Our studies indicate that 14-3-3 proteins are also
involved in the trafficking of proteins from the plasma membrane
to the E/L system. Co-expression of Wt MLN64 with the 14-3-3
antagonist DIFOPEIN delays MLN64 trafficking to the late
endosome (Figure 7D) similarly to the results with the MLN64
binding site mutant alone (Figure 6), suggesting that trafficking of
MLN64 to the late endosome via the plasma membrane is
enhanced by binding to 14-3-3. The importance of 14-3-3
interactions for the internalization of two other proteins to the
E/L system has very recently been described [30,31].
Because MLN64 appears to reach the late endosome eventually,
its localization is likely not entirely dependent on interaction with
14-3-3. Instead, it may be that the interaction with 14-3-3
enhances MLN64 endosomal localization by inhibiting its
interaction with another protein that would keep it tethered to
the plasma membrane. The act of blocking access to other protein
partners has emerged as a common mechanism by which 14-3-3
proteins mediate their effects on protein trafficking. Through this
mechanism, 14-3-3 can effect the forward transport of ion
channels [32], which contain retention motifs that bind to
cytosolic COPI (coatamer I)-coated vesicles for retrograde
transport to the ER [26]. Properly assembled proteins must
overcome this ER quality control mechanism to reach the plasma
Figure 5. The MLN64 START domain is important for interactions with 14-3-3. A) An atypical 14-3-3 binding site at position 392 of the
START domain of MLN64. B) According to a ribbon diagram of the crystal structure of the START domain, the predicted 14-3-3 binding site lies in an
exposed loop (yellow) on the surface of the protein. C) Immunoprecipitation and western blot analysis of lysates from cells transfected with either
MLN64-Flag (Wt) or MLN64*-Flag (Mut) indicates that the mutant MLN64 protein displays greatly reduced binding to the g isoform relative to the Wt
protein. e* denotes a 14-3-3 isoform that cannot bind target proteins. D) Similar to Figure 3A, Western blot analysis of expressed mutant MLN64*-Flag
from cell lysates bound to purified GST-tagged 14-3-3 isoforms indicates little or no interaction of mutant MLN64* and 14-3-3 c, e, g, f, t and s
isoforms.
doi:10.1371/journal.pone.0034424.g005
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proteins prevents COPI binding and promotes protein movement
to the cell surface. This mechanism of 14-3-3 masking has been
demonstrated for the ER exit-motifs on potassium channels, an
acetylcholine receptor and an immune system complex [28].
Similarly, 14-3-3 enhances the nuclear localization of telomerase
by inhibiting its interactions with exportin-1, which mediates its
nuclear export [22].
In the absence of 14-3-3 binding, MLN64-positive organelles
disperse to the cell periphery (Figure 7B and 7C). Endosomal
dispersion has been described in cells treated with the actin-
depolymerizing drug cytochalasin and in cells depleted of LIM
kinase [33], which is involved in actin-mediated dynamics.
Endosomal dispersion has also been described in cells depleted
of MLN64 by siRNA and was attributed to loss of MLN64-
mediated interactions between the late-endosomal membrane and
the actin cytoskeleton [5]. However, to date no direct connection
between actin and MLN64 has been demonstrated. Our
observations that DIFOPEIN expression results in endosomal
dispersal (Figure 7B and C) similar to pharmacologic actin
disruption and MLN64 depletion indicate that 14-3-3 interactions
with MLN64 may mediate its effects on the actin cytoskeleton. 14-
3-3 itself is implicated in actin cytoskeleton dynamics by binding
and stabilizing the actin-depolymerizing factor cofilin [34]. Taken
Figure 6. Expression of mutant MLN64 causes aberrant MLN64 and lipid trafficking in cells. A) Expression of either Wt or mutant MLN64
protein (red) in cells results in some co-localization with CD63-YFP (green); however, Wt MLN64 appears primarily vesicular, whereas mutant MLN64
exhibits more plasma membrane staining. Nuclei (blue) were stained with Hoechst 33342. B) Expression of either Wt or mutant MLN64 protein
(green) results in accumulation of free cholesterol (blue) and GM1 (red) in endocytic vesicles. Cells transfected with mutant MLN64 accumulated more
cholesterol than cells transfected with Wt MLN64; however, the levels of GM1 in both cell types were the equivalent. C) Quantitation of cholesterol
accumulation in cells expressing either Wt MLN64 (Wt) or mutant MLN64* (Mut). AU; arbitrary units.
doi:10.1371/journal.pone.0034424.g006
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34424together, these results point toward a role for 14-3-3 in MLN64-
mediated actin cytoskeleton dynamics. Future work should
delineate the specifics of the interplay between MLN64, 14-3-3,
and the actin cytoskeleton and also determine whether 14-3-3 may
interact with other START domain-containing proteins.
Materials and Methods
Materials
All chemicals and M2 Flag antibody were from Sigma-Aldrich
(St. Louis, MO) unless otherwise noted. All other antibodies, goat
serum,andproteinA/GbeadswerefromSantaCruzBiotechnology
(Santa Cruz, CA, U.S.A.). Filipin was from PolySciences, Inc.
(Warrington, PA). Affigel 10 beads were from Bio-Rad (Hercules,
CA). Paraformaldehyde was from Electron Microscopy Sciences
(Hatfield, PA). LIpofectamine Plus and Alexa Fluor 594 cholera
toxin subunit B were from Invitrogen (Carlsbad, CA). Fugene 6 was
from Roche (Indianapolis, IN).
Cell Lines and Tissue Culture
COS7 and MCF7 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM), CHO-K1 cells were cultured in 50%
HAM’s/50% DMEM and Huh7 cells were cultured in RPMI. All
media were supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, and 50 mg/ml gentamicin for cell propagation. Cells
were maintained in a humidified incubator at 37uC and 5% CO2.
COS7 cells were transfected with Lipofectamine Plus reagent, and
Huh7 cells were transfected with Fugene6 (Roche).
Cloning
Full length MLN64 (GenBank accession no. X80198) was PCR-
amplified from a human liver cDNA library (Clontech, Mountain
View, CA) and cloned in frame with a 3xFlag tag into the pIRES-
hrGFP-1a expression vector (Stratagene, La Jolla, CA) (MLN64-
Flag). To visualize proteins without GFP expression, the GFP
coding sequences were excised out of the vector. For the
transmembrane (TM) region, nucleotides corresponding to amino
acids 1–171 were used, and for the START domain, nucleotides
corresponding to amino acids 172–445 were used.
To generate an MLN64 protein mutant (MLN64*-Flag)
deficient in 14-3-3 binding, a mutation was introduced at one
14-3-3 potential binding site in the START domain of MLN64:
the amino acid sequence KSASN at positions 392–396 was
replaced with 5 alanine residues using the megaprimer method
[35].
To generate the CD63-YFP fusion, human CD63 (ATCC;
IMAGE clone 2819554) was cloned into EYFP-C1 (Clontech) in-
frame with YFP. The eYFP was rendered monomeric by
introducing the mutation L221K [36].
Antibody Generation
MLN64 polyclonal antibodies were produced against the
START domain of MLN64, spanning nucleotides 526–1335 from
thestartcodon(aminoacids176–445).Thefragmentwasisolatedby
PCR from a human liver cDNA library using the primers 59-
GCGGATCCCAGGAAGCTGAAGAGGAGCGA TGGTATCT-
39 and 59-GCGCTCGAGCGCCCG GGCCCCCAGCT-39 and
cloned into the bacterial expression vector pET29a-TRX [37]. The
resulting product was sequence verified and expressed in BL21
pLysS bacteria as described [38]. The MLN64 fragment-His6
fusion protein was purified on a nickel-affinity column under
denaturing conditions and resolved by SDS/12% PAGE. The
protein band was excised and used to immunize NewZealand white
rabbits.
Affinity Purification and Identification of MLN64-
interacting Proteins
The bacterially expressed START domain protein was used to
generate an affinity column by immobilization to AffiGel 10 beads
according to the manufacturer’s recommendations. MCF7 cell
lysates were prepared by resuspending the cell pellet in ice-cold
MLN64 Lysis Buffer (10 mM Tris pH 8, 150 mM NaCl, 1 mM
CaCl2, 1 mM MgCl2, 1% Triton-X 100) with protease inhibitor
cocktail solution (1 ml/20 mg protein). The cell suspension was
incubated for 30 min on ice and then cleared by centrifugation at
10,000 g for 15 min and applied to the column. Fractions were
eluted from the column with increasing NaCl concentrations and
resolved by SDS/PAGE electrophoresis.
For the blot overlay, the 400 mM NaCl elution fraction was
resolved by SDS/PAGE, transferred to nitrocellulose and overlaid
with recombinant START protein. The membrane was then
probed with anti-MLN64 antibody and secondary anti-rabbit
antibodies conjugated with horseradish peroxidase. Proteins were
visualized by chemiluminescence using SuperSignal West Dura
substrate (Thermo Scientific, Rockford, IL).
Mass Spectrometric Analysis
Protein bands of interest separated by SDS/PAGE were excised
from the gel, destained, and reduced with 10mM TCEP, alkylated
by 50 mM iodoacetamide, followed by digestion with trypsin
(100 ng per band in 50 mM ammonium bicarbonate (ABC)). The
tryptic peptides were extracted by using POROS 20 R2 beads
(Applied Biosystems) in the presence of 5% formic acid and 0.2%
trifluoracetic acid and dried in a vacuum concentrator. The
resulting peptides were dissolved in 3–8 ml of HPLC sample
solvents containing water:methanol:acetic acid:TFA
(70:30:0.5:0.01, vol/vol/vol/vol). Micro-HPLC-MS/MS analysis
was conducted on an LCQ electrospray ionization ion trap mass
spectrometer (ThermoFinnigan) coupled with an online
Figure 7. Lack of 14-3-3 binding causes delayed trafficking of MLN64 to the endosomal system. A) Huh7 cells transfected with MLN64-
Flag (Wt) or MLN64*-Flag (Mut) for 24 hours were incubated at 20uC for 2 hr to cause accumulation of the protein at the Golgi. Immediately
preceding release from the block, MLN64 proteins (green) exhibited a perinuclear staining pattern characteristic of the Golgi (t = 0). Shortly after
release from the block, Wt MLN64 is found in both vesicular compartments and the plasma membrane (t=15, t=30), in contrast to mutant MLN64,
which remains primarily in the Golgi at 15 minutes. Only a small population of mutant protein appears on the plasma membrane and in vesicles at 30
minutes. Nuclei were counterstained with Hoechst 33342 (blue signal). B) MLN64-positive late endosomes (red) exhibit dissimilar localization in Huh7
cells transfected with DIFOPEIN-YFP or YFP alone (green) for 24 hrs. In YFP-expressing cells, MLN64 exhibits a characteristic perinuclear distribution,
whereas in cells expressing DIFOPEIN-YFP, in which 14-3-3-ligand interactions are blocked, MLN64 recedes to the cell periphery. C) Co-expression of
YFP (green) and MLN64-Flag (red) in Huh7 cells does not affect the normal perinuclear distribution of endosomes. In contrast, co-expression of
DIFOPEIN-YFP with MLN64-Flag causes MLN64-positive vesicles to disperse toward the cell periphery, similarly to the effect seen in B. D) Huh7 cells
transfected with MLN64-Flag and either DIFOPEIN-YFP or YFP alone were subjected to a temperature block at 20uC as described in A. At t=0, MLN64
exhibits the perinuclear staining pattern that is characteristic of the Golgi. After release from the block, cells transfected with DIFOPEIN-YFP are
localized mainly at the plasma membrane, with a small population being localized to vesicular compartments (t=30). In contrast, cells transfected
with YFP alone localize mainly in vesicular compartments, with a small population located at the plasma membrane.
doi:10.1371/journal.pone.0034424.g007
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sprayed directly into the LCQ mass spectrometer (3.6 kV) and
data was collected and analyzed using the program KNEXUS
(Genomic Solutions).
Protein Methods
For the glutathione-S-transferase (GST) pull-down assay, GST-
tagged 14-3-3 constructs were kindly provided by Peter Mundel
(Mount Sinai School of Medicine). The GST proteins were
expressed in bacteria, purified using glutathione-coupled agarose,
and used in immunoprecipitation assays as described previously
[39].
For protein co-immunoprecipitation, cell lysates were prepared
in 1 ml of cold co-IP buffer (50 mM Tris pH8, 100 mM NaCl,
5 mM EDTA, 1% Triton X, 0.5% deoxycholate, 10% glycerol)
and centrifuged at 10,000 g for 15 min at 4uC to precipitate
insoluble debris. Lysates were diluted to 1 mg/ml with cold co-IP
buffer and were pre-cleared by incubation with 50 ml protein A/G
beads at 4uC for 30 minutes with rocking, followed by
centrifugation at 2,000 g for 10 min at 4uC. The precleared
lysates were incubated with 2 mg antibody for 16 hr at 4uCo na
rocker, followed by incubation with 100 ml protein A/G beads for
2 hours at 4uC on a rocker. The beads were collected by
centrifugation at 2,000 g for 10 s and then gently washed 565
minutes with 1 ml of cold PBS in IP wash buffer (20 mM Tris
pH 8, 1 mM EDTA, 100 mM NaCl, 0.5% Triton-X 100). Beads
were resuspended in 100 ml of 5X Laemmli Buffer, heated at 70uC
for 10 minutes, centrifuged and used for SDS/PAGE electropho-
resis and Western blot analysis as previously described [40].
Immunocytochemistry
Cells were grown on glass coverslips to 60–80% confluency and
transfected according to the manufacturer’s recommendations. At
24 hours post transfection, cells were fixed with 4% paraformal-
dehyde in PBS for 30 min and permeabilized with 0.1% Triton-X
100 in PBS/10% normal goat serum (NGS) for 30 min followed
by incubation with primary antibodies for 1 hour at room
temperature. Antibodies were diluted in PBS supplemented with
0.05% Triton-X 100 and 10% NGS. Following incubation with
primary antibodies, cells were washed 365 minutes in PBS
containing 0.05% Triton-X 100. Cells were then incubated with
secondary antibodies that were diluted 1:1000 in PBS supple-
mented with 0.05% Triton-X 100 and 10% NGS for 40 min at
room temperature and then 365 minutes in PBS with 0.05%
Triton-X 100. After a final wash for 5 minutes in PBS, coverslips
were mounted onto microscope slides using Fluoromount-G
(SouthernBiotech, Birmingham, AL) and analyzed on a Nikon
fluorescence microscope fitted with a CCD (charge-coupled-
device) camera. Images were acquired with the MetaVue software
package and then deconvoluted using AutoDeblur software from
AutoQuant Imaging.
For labeling with filipin and antibodies, cells were permeabilized
with 0.2% saponin in PBS/10% NGS for 30 min. Primary and
secondary antibodies were diluted in PBS supplemented with
50 mg/ml filipin, 0.05% saponin, and 10% NGS. Cells were
washed 365 minutes in PBS containing 0.05% saponin and then
mounted and analyzed as described above.
For temperature block studies, transfected cells were placed in a
20uC incubator for 2 hr, after which they were returned to a 37uC
incubator for the indicated times before processing.
Cholesterol Esterification
Cholesterol esterification assays were performed essentially as
previously described [41]. LDL-specific cholesterol esterification
was determined by subtracting esterification rates from LDL-plus
vs. LDL-minus cells [42].
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